Inflammatory Bowel Diseases最新文献

{"title":"Past But Not Forgotten: Innate Factors Affect the Course of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease.","authors":"Georgios Kokkotis, Giorgos Bamias","doi":"10.1093/ibd/izaf105","DOIUrl":"10.1093/ibd/izaf105","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2604-2606"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144011143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patients With Crohn's Disease and Terminal Ileum Resection are at Increased Risk of Colorectal Cancer: A Population-Based Study.","authors":"Inas Mikhail, Omar Al Ta'ani, Razan Aburumman, Saqr Alsakarneh, Francis A Farraye, Jana G Hashash","doi":"10.1093/ibd/izaf118","DOIUrl":"10.1093/ibd/izaf118","url":null,"abstract":"<p><p>Patients with Crohn's disease (CD) who undergo terminal ileum (TI) resection experience altered bile acid absorption, which may influence colorectal cancer (CRC) risk. We conducted a propensity-matched cohort study using TriNetX to compare CRC risk in patients with CD who underwent TI resection versus those who did not. Terminal ileum resection was associated with an increased risk of CRC (aHR = 2.58, 95% CI, 1.72-3.86). Patients with TI resection also had higher odds of colorectal polyps. These findings suggest the need for heightened CRC surveillance in patients with CD undergoing TI resection.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2593-2596"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Multicenter Study to Assess Avoidant/Restrictive Food Intake Disorder in Patients with Inflammatory Bowel Disease.","authors":"Laurie B Grossberg, Kajali Mishra, Loren G Rabinowitz, Benjamin Mecsas-Faxon, Nivedita Mandal, Ammu Susheela, Amar Naik, Krishna Patel, Marissa Gallotto, Tara Greenwood, Helen Burton Murray, Konstantinos Papamichael, Adam S Cheifetz, Sarah W Kinsinger, Sarah Ballou","doi":"10.1093/ibd/izaf016","DOIUrl":"10.1093/ibd/izaf016","url":null,"abstract":"<p><strong>Background and aims: </strong>Disordered eating is frequently reported in patients with inflammatory bowel disease (IBD). We aimed to describe the prevalence of avoidant restrictive food intake disorder (ARFID) in patients with IBD and to identify predictors of ARFID.</p><p><strong>Methods: </strong>Patients with IBD at 2 academic medical centers completed questionnaires including the ARFID subscale of the Pica, ARFID, and Rumination Disorder Questionnaire (PARDI-AR-Q), disease characteristics, and psychosocial variables. IBD disease activity was determined by a review of objective data within 90 days of survey completion.</p><p><strong>Results: </strong>Three hundred and twenty-five participants completed the questionnaires (56% female, average age 47.60 years, 49.5% Crohn's disease (CD), 45.5% ulcerative colitis (UC)). Using the PARDI-AR-Q, 17.8% of the total sample screened positive for ARFID. ARFID+ respondents were younger, had shorter disease duration, and worse psychosocial functioning compared to ARFID-. A higher percentage of ARFID+ patients had objective disease activity compared to ARFID- (51% vs. 40%), but this was not statistically significant. There was no statistical difference in ARFID rates between patients with CD compared to UC. In patients with inactive disease only, 16.3% screened positive for ARFID. In hierarchical logistic regression, the only significant predictor of ARFID among patients with inactive IBD was GI-specific anxiety.</p><p><strong>Conclusions: </strong>In this multi-center study, 16.3% of patients with inactive IBD met the criteria for ARFID, and 17.8% of all patients met the criteria regardless of objective disease activity. GI-specific anxiety was the only predictor of ARFID among patients with inactive IBD, highlighting the need for multidisciplinary care in IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2381-2389"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12455582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Monitoring of Inflammatory Bowel Disease in Mice Using Endoscopic Optical Coherence Tomography.","authors":"Muktesh Mohan, Oana-Maria Thoma, Shivani Sharma, Gargi Sharma, Markus F Neurath, Maximillian Waldner, Kanwarpal Singh","doi":"10.1093/ibd/izaf045","DOIUrl":"10.1093/ibd/izaf045","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD) is one of the fastest-growing diseases globally. Nearly 5 million people are affected by IBD, with an incremental growth rate of 47.45% between 1990 and 2019.</p><p><strong>Aim and methods: </strong>We aim to provide a noninvasive approach to detecting IBD with an in-house developed 1310 nm endoscopic optical coherence tomography (OCT) system. Mice with acute colitis underwent a longitudinal colon imaging process for real-time and long-run disease progression. The OCT images were processed and segmented using a computer vision image processing-based segmentation algorithm for further thickness mapping and attenuation coefficient calculations.</p><p><strong>Result: </strong>An increase in overall colon wall thickness due to inflammation was observed, as well as a reduction in attenuation coefficient due to a change in refractive index.</p><p><strong>Conclusion: </strong>Comparable results with white light endoscope and histological examination suggest the clinical potential of the 1310 nm endoscopic OCT system for in vivo assessment of IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2477-2486"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Identification of the M2 Macrophage-associated Gene THBS2 as a Predictive Marker for Inflammatory Cancer Transformation.","authors":"","doi":"10.1093/ibd/izaf102","DOIUrl":"10.1093/ibd/izaf102","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2612"},"PeriodicalIF":4.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.","authors":"Uma Mahadevan, Cynthia H Seow, Edward L Barnes, María Chaparro, Emma Flanagan, Sonia Friedman, Mette Julsgaard, Sunanda Kane, Siew Ng, Joana Torres, Gillian Watermeyer, Jesus Yamamoto-Furusho, Christopher Robinson, Susan Fisher, Phil Anderson, Richard Gearry, Dana Duricova, Marla Dubinsky, Millie Long","doi":"10.1093/ibd/izaf171","DOIUrl":"https://doi.org/10.1093/ibd/izaf171","url":null,"abstract":"<p><strong>Background & aims: </strong>Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data.</p><p><strong>Methods: </strong>The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health.</p><p><strong>Results: </strong>The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements.</p><p><strong>Conclusions: </strong>Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RELA Haploinsufficiency Manifesting as an Atypical Phenotype of Crohn's Disease.","authors":"Noa Tal, Liran Baram, Arne Gehlhaar, Weihong Gu, Siqi Guo, Eduardo Gonzalez Santiago, Atar Lev, Ortal Barel, Raanan Shamir, Raz Somech, Liza Konnikova, Dror S Shouval","doi":"10.1093/ibd/izaf159","DOIUrl":"https://doi.org/10.1093/ibd/izaf159","url":null,"abstract":"<p><strong>Background: </strong>Mutations in RELA, a key component of NF-κB signaling, are associated with dysregulated immune responses and inflammatory disorders. While immunodeficiency phenotypes associated with RELA haploinsufficiency have been reported, gastrointestinal manifestations remain poorly described. This study aimed to characterize the clinical, genomic, and immunological features of a patient presenting with an atypical Crohn's-like phenotype driven by RELA haploinsufficiency.</p><p><strong>Methods: </strong>Whole-exome sequencing was performed, and results were confirmed by Sanger sequencing. Protein modeling, Western blotting, immunofluorescence, and nuclear extract-based NF-κB activation assays were conducted to assess the functional impact of the identified variant. Immune profiling was performed using mass cytometry time of flight (CyTOF) and single-cell RNA sequencing (scRNA-seq) and compared to controls.</p><p><strong>Results: </strong>We studied a 17-year-old male diagnosed with pan-enteric Crohn's disease (CD), perianal fistulas, chronic mucocutaneous candidiasis, and chronic lymphopenia. Sequencing identified a heterozygous missense variant in RELA (c.587T>C, p.V196A) that potentially impairs RelA (p65) protein stability, confirmed by reduced activity and diminished protein expression. CyTOF analysis revealed decreased circulating T regulatory cells (Tregs), absence of mucosal Tregs, high apoptotic rates, and elevated IFN-γ induced levels, while scRNA-seq demonstrated a robust type I/II interferon signature in multiple immune subsets. Dysregulated mucosal-associated invariant T (MAIT) and cytotoxic CD4+ T cells exhibited upregulation of IL23R and ADAM12, further linking RELA dysfunction to enhanced pro-inflammatory T cell response and tissue inflammation.</p><p><strong>Conclusion: </strong>This study links RELA haploinsufficiency with CD-like features, Th1/Th17 polarization, and interferon-driven inflammation, emphasizing the importance of genetic evaluation in patients with atypical or refractory IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Outcomes of Patients with Crohn's Disease Treated with Risankizumab.","authors":"Grace Geeganage, Ajay Gade, Alessandra Saraga, Tina Deyhim, Samantha Zullow, Loren G Rabinowitz, Adam S Cheifetz, Laurie B Grossberg, Konstantinos Papamichael","doi":"10.1093/ibd/izaf162","DOIUrl":"https://doi.org/10.1093/ibd/izaf162","url":null,"abstract":"<p><strong>Background: </strong>Cumulative data suggest that risankizumab is an effective and safe treatment for patients with Crohn's disease (CD). However, most of the data derive from randomized controlled trials or small retrospective studies with short- or mid-term follow-up. This study aimed to assess the long-term effectiveness and safety of risankizumab in a real-world cohort of patients with CD.</p><p><strong>Methods: </strong>This single-center, retrospective, cohort study included consecutive patients with CD treated with risankizumab from October 2022 to August 2024. A time-to-event analysis was performed for treatment failure, treatment escalation, and CD-related health care utilization. Treatment failure was defined as the need for drug discontinuation due to primary nonresponse, loss of response, or a serious adverse event or the need for IBD (inflammatory bowel disease)-related surgery. Treatment escalation was defined as the need for shortening the dose interval or intravenous reinduction due to breakthrough CD-related symptoms and/or elevated biomarkers, such as C-reactive protein and fecal calprotectin. Health care utilization was defined as CD-related emergency department visit or hospitalization. Patients were followed from start of risankizumab until drug discontinuation or the end of follow-up (October 2024).</p><p><strong>Results: </strong>The study population consisted of 106 patients with CD (74% receiving prior biological therapies). Patients were followed for a median of 12 [interquartile range (IQR), 6.8-18.8] months; 14 (13%) patients had treatment failure; 24 (23%) had treatment escalation; and 17 (16%) had CD-related health care utilization. Multivariable Cox proportional hazards regression analysis identified penetrating CD as associated with treatment failure [hazard ratio (HR), 5.2; 95% confidence interval (CI), 1.6-17.2; P = .007], while perianal fistulizing CD (HR, 3.3; 95% CI, 1.2-9.4; P = .023) and prior exposure to more than 2 biologics (HR, 5.8; 95% CI, 1.3-26.3; P = .022) were associated with treatment escalation.</p><p><strong>Conclusion: </strong>In this real-world cohort with long-term follow-up, risankizumab was generally effective in patients with CD. Penetrating CD was associated with treatment failure, while perianal fistulizing CD and prior exposure to more than 2 biologics were associated with treatment escalation.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tissue MicroRNA Expression Signatures as Diagnostic Biomarkers and Predictors of Residual Disease Activity and Relapse in Treatment-Naïve Pediatric Inflammatory Bowel Disease.","authors":"Tereza Deissova, Dagmar Al Tukmachi, Lenka Radova, Julia Bohosova, Tana Machackova, Leos Kren, Matej Hrunka, Tereza Pinkasova, Martina Ambrozova, Jiri Sana, Ondrej Slaby, Petr Jabandziev","doi":"10.1093/ibd/izaf120","DOIUrl":"https://doi.org/10.1093/ibd/izaf120","url":null,"abstract":"<p><strong>Background: </strong>Identifying novel diagnostic and prognostic biomarkers for pediatric inflammatory bowel diseases (PIBD), including Crohn's disease (pCD) and ulcerative colitis (pUC), is essential for enhancing treatment outcomes. MicroRNAs (miRNAs) have been recognized for their broader relevance in PIBD pathogenesis. This study investigates their diagnostic potential and clinical utility in PIBD.</p><p><strong>Methods: </strong>This prospective, monocentric study, with retrospective validation, involved 119 PIBD patients (58 pCD, 61 pUC) and 39 non-IBD controls. Small RNA next-generation sequencing was performed on fresh-frozen gut biopsies, targeting histopathologically confirmed inflamed areas. Twenty-five dysregulated miRNA candidates were validated via RT-qPCR in formalin-fixed, paraffin-embedded gut biopsies. Logistic regression was used to establish diagnostic and prognostic miRNA expression signatures.</p><p><strong>Results: </strong>A diagnostic signature of 5 miRNAs (miR-223-3p, miR-34a-5p, miR-194-5p, miR-215-5p, miR-338-3p) distinguished pCD from non-IBD with 96.49% accuracy. Two miRNAs (miR-223-3p, miR-194-5p) differentiated pUC from non-IBD with 100% accuracy, and miR-215-5p distinguished pCD from pUC specimens with 83.54% accuracy. For treatment-naïve pCD patients, 7 miRNAs predicted residual disease activity at 3 months with 100% accuracy. Additionally, a distinct signature predicted the risk of relapse within 12 months with an accuracy of 84.21%.</p><p><strong>Conclusions: </strong>In this study, we have established tissue miRNA expression signatures with significant diagnostic and prognostic potential for use in PIBD. These findings aid in stratifying disease severity and risk, paving the way for more precise and personalized management of pediatric IBD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-Life Body Mass Index and Inflammatory Bowel Disease Risk: A Scandinavian Birth Cohort Study.","authors":"Tereza Lerchova, Johnny Ludvigsson, Staffan Mårild, Henrik Imberg, Björn Andersson, Ketil Størdal, Karl Mårild","doi":"10.1093/ibd/izaf167","DOIUrl":"https://doi.org/10.1093/ibd/izaf167","url":null,"abstract":"<p><strong>Introduction: </strong>Childhood overweight and obesity are emerging global health issues with potential implications for immune function. We aimed to investigate childhood body mass index (BMI) as a risk factor for later inflammatory bowel disease (IBD).</p><p><strong>Methods: </strong>ABIS (Sweden) and MoBa (Norway) are population-based cohorts following participants prospectively from birth (1997-2009) until 2023. We retrieved anthropometric data at birth, 1, 3, and 7-8 years to examine the association of age-specific standardized BMI percentiles and categories (underweight, normal [reference), overweight, obesity) with later IBD. We also analyzed IBD risk according to BMI trajectories across ages. IBD diagnosis was identified in national health registries. Cohort-specific hazard ratios (aHRs) were adjusted for sociodemographics, parental BMI, IBD, and smoking and pooled using a random-effects model.</p><p><strong>Results: </strong>Overall, among 54 890 children with 803 444 person-years of follow-up, we identified 246 IBD events. Eight-year-olds living with obesity had a 5-fold increased risk of ulcerative colitis (pooled aHR = 5.10; 95% CI , 1.51-17.27), but not a significantly increased risk of Crohn's disease (pooled aHR = 1.38; 95% CI , 0.24-7.98) and IBD overall (pooled aHR = 1.89; 95% CI , 0.71-5.04). Children with overweight or obesity at age 3 had no increased risk of IBD compared to normal-weight children (pooled aHR = 1.15, 95% CI , 0.74-1.77; and 1.05, 95% CI , 0.43-2.58, respectively). Early-life BMI trajectories were not consistently associated with IBD.</p><p><strong>Conclusion: </strong>In this Scandinavian birth cohort, 7-8 year-old children with obesity had an increased risk of developing ulcerative colitis later in life. Given the high prevalence of childhood obesity, this observation should be corroborated and possible mechanisms behind the association clarified.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144952721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}